Onerva Levälampi

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The purpose of this work was to carry out preclinical toxicity and bio-distribution studies required for regulatory approval of a clinical trial application for Phase I clinical studies of ONCOS-102 (Ad5/3-D24-GM-CSF) for therapy of advanced cancers (NCT01598129). The study design, route of administration and dosage differs from the clinical protocol and in(More)
  • 1